# EDGAR Filing Document

**Accession Number:** 0001770787
**File Stem:** 0001770787-25-000048
**Filing Date:** 2025-8
**Character Count:** 19679
**Document Hash:** 4ba3dc9651104359939b911d2a6b9255
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001770787-25-000048.hdr.sgml**: 20250807

**ACCESSION NUMBER**: 0001770787-25-000048

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250807

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250807

**DATE AS OF CHANGE**: 20250807

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 10x Genomics, Inc.
- **CENTRAL INDEX KEY:** 0001770787
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 455614458
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39035
- **FILM NUMBER:** 251194066

**BUSINESS ADDRESS:**
- **STREET 1:** 6230 STONERIDGE MALL ROAD
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588
- **BUSINESS PHONE:** (925) 401-7300

**MAIL ADDRESS:**
- **STREET 1:** 6230 STONERIDGE MALL ROAD
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 10X Genomics, Inc.
- **DATE OF NAME CHANGE:** 20190315

?xml version='1.0' encoding='ASCII'? txg-20250807

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**______________________**

**FORM 8-K**

**______________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 7, 2025**

![Logo-10x.jpg](txg-20250807_g1.jpg)

**10x Genomics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39035** | **45-5614458** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**6230 Stoneridge Mall Road**

**Pleasanton, California 94588**

**(925) 401-7300**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**___________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol** | **Name of each exchange**<br>**on which registered** |
| **Class A common stock, par value $0.00001 per share** | **TXG** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On August 7, 2025, 10x Genomics, Inc. (the "Company") issued a press release announcing the Company's financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;(d)*Exhibits.*

---

| | |
|:---|:---|
| Exhibit No. | Description of Exhibits |
| 99.1 | <u>[Press Release dated August 7, 2025.](txg-20250807xexx991.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | 10x Genomics, Inc. | 10x Genomics, Inc. |
| | By: | /s/ Eric S. Whitaker |
| | Name: | Eric S. Whitaker |
| | Title: | Chief Legal Officer |
| Date: August 7, 2025 |  |  |

---

## Exhibit 99.1

**Exhibit 99.1**

![a10x_logoxhorizontalxfullc.jpg](a10x_logoxhorizontalxfullc.jpg)

**10x Genomics Reports Second Quarter 2025 Financial Results**

**PLEASANTON, Calif.** August 7, 2025 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2025.

**Recent Updates** 

&nbsp;&nbsp;&nbsp;&nbsp;• Revenue was $172.9 million for the second quarter. Excluding $27.3 million related to a patent litigation settlement, revenue was $145.6 million.

&nbsp;&nbsp;&nbsp;&nbsp;• Ended the second quarter with cash and cash equivalents and marketable securities of $447.3 million, representing a $20 million increase over the prior quarter.

&nbsp;&nbsp;&nbsp;&nbsp;• Entered into a definitive agreement to acquire Scale Biosciences for upfront cash and stock consideration of $30 million, plus contingent consideration that could become payable upon the achievement of certain milestones. The acquisition strengthens the company's leadership in single cell analysis with key technology that will drive innovation and expand access by enabling more powerful, affordable and scalable experiments across a broader range of applications.

&nbsp;&nbsp;&nbsp;&nbsp;• Began shipping Visium HD 3' and HD cell segmentation, expanding the Visium portfolio's capabilities by enabling high-resolution, high-sensitivity profiling across a wider range of applications.

&nbsp;&nbsp;&nbsp;&nbsp;• Announced a partnership with the Genome Institute of Singapore on the TISHUMAP initiative, which will leverage Xenium and AI to uncover novel biomarkers and therapeutic targets for cancer and inflammatory diseases.

"The second quarter unfolded largely as anticipated," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Amid continued uncertainty in the funding environment, we're encouraged by the resilience of our business and the dedication of our team. We're focused on disciplined execution, and remain confident in the strength of our technology, the momentum behind our platforms and the significant long-term opportunity in front of us."

**Second Quarter 2025 Financial Results**

Revenue was $172.9 million for the second quarter of 2025. Excluding $27.3 million related to a patent litigation settlement, revenue was $145.6 million, a 5% decrease from the corresponding period of 2024, primarily driven by a decrease in instrument revenue. This figure also reflects approximately $4.0 million of revenue that resulted from customers in China accelerating purchases from the third quarter into the second quarter in anticipation of potential tariff changes.

Gross margin was 72% for the second quarter of 2025, as compared to 68% for the corresponding prior year period. The increase in gross margin was primarily due to higher license and royalty revenue and lower royalties and warranty costs, partially offset by an increase in inventory reserves and higher manufacturing costs. Excluding the impact of license and royalty revenue, gross margin was 67% for the second quarter of 2025.

Operating expenses were $95.0 million for the second quarter of 2025, a 35% decrease from $146.0 million for the corresponding prior year period. The decrease was primarily driven by a $40.7 million gain on settlement related to the litigation settlement.

Operating income was $30.1 million for the second quarter of 2025, as compared to operating loss of $41.7 million for the corresponding prior year period.

Net income was $34.5 million for the second quarter of 2025, as compared to a net loss of $37.9 million for the corresponding prior year period.

Cash and cash equivalents and marketable securities were $447.3 million as of June 30, 2025.

------

![a10x_logoxhorizontalxfullc.jpg](a10x_logoxhorizontalxfullc.jpg)

**Third Quarter 2025 Revenue Guidance**

10x Genomics expects third quarter 2025 revenue to be in the range of $140 million to $144 million. This guidance reflects approximately $4.0 million of revenue that resulted from customers in China accelerating purchases from the third quarter into the second quarter in anticipation of potential tariff changes.

**Webcast and Conference Call Information**

10x Genomics will host a conference call to discuss the second quarter 2025 financial results, business developments and outlook after market close on Thursday, August 7, 2025 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at <u>http://investors.10xgenomics.com</u>. The webcast will be archived and available for replay at least 45 days after the event.

**About 10x Genomics**

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit <u>10xgenomics.com</u> or connect with us on <u>LinkedIn</u>, <u>X</u>, <u>Facebook</u>, <u>Bluesky</u> or <u>YouTube</u>.

**Forward Looking Statements**

**Disclosure Information**

10x Genomics uses filings with the Securities and Exchange Commission, its website (<u>www.10xgenomics.com</u>), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

**Contacts**

Investors: <u>investors@10xgenomics.com</u>

Media: <u>media@10xgenomics.com</u>

------

![a10x_logoxhorizontalxfullc.jpg](a10x_logoxhorizontalxfullc.jpg)

**10x Genomics, Inc.**

**Condensed Consolidated Statements of Operations**

*(Unaudited)*

*(In thousands, except share and per share data)*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Products and services revenue <sup>(1)</sup> | $145157 | $152990 | $282980 | $293995 |
| License and royalty revenue <sup>(1)</sup> | 27751 | 114 | 44811 | 115 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue | 172908 | 153104 | 327791 | 294110 |
| Cost of products and services revenue <sup>(2)</sup> | 47824 | 48884 | 97262 | 96976 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 125084 | 104220 | 230529 | 197134 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development <sup>(2)</sup> | 61224 | 62918 | 125469 | 131556 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative <sup>(2)</sup> | 74434 | 83039 | 164162 | 168813 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on settlement | (40700) |  | (49900) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 94958 | 145957 | 239731 | 300369 |
| Income (loss) from operations | 30126 | (41737) | (9202) | (103235) |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | 4271 | 4715 | 7957 | 9451 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (3) | (1) | (3) | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (expense), net | 2603 | (56) | 4739 | (1096) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income | 6871 | 4658 | 12693 | 8353 |
| Income (loss) before provision for income taxes | 36997 | (37079) | 3491 | (94882) |
| Provision for income taxes | 2459 | 818 | 3311 | 2964 |
| Net income (loss) | $34538 | $(37897) | $180 | $(97846) |
| Net income (loss) per share, basic | $0.28 | $(0.32) | $— | $(0.82) |
| Net income (loss) per share, diluted | $0.28 | $(0.32) | $— | $(0.82) |
| Weighted-average shares used to compute net income (loss) per share, basic | 123755409 | 120066972 | 123183924 | 119461485 |
| Weighted-average shares used to compute net income (loss) per share, diluted | 124509720 | 120066972 | 124258150 | 119461485 |

---

------

![a10x_logoxhorizontalxfullc.jpg](a10x_logoxhorizontalxfullc.jpg)

(1)The following table represents revenue by source for the periods indicated (in thousands). Spatial products includes the Company's Visium and Xenium products:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Instruments** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Chromium | $5727 | $8792 | $11640 | $16642 |
| &nbsp;&nbsp;&nbsp;&nbsp;Spatial | $8770 | 15060 | $17672 | 32663 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total instruments revenue** | 14497 | 23852 | 29312 | 49305 |
| **Consumables** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Chromium | 85788 | 94108 | 169897 | 178035 |
| &nbsp;&nbsp;&nbsp;&nbsp;Spatial | 36397 | 29254 | 67644 | 55662 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total consumables revenue** | 122185 | 123362 | 237541 | 233697 |
| **Services** | 8475 | 5776 | 16127 | 10993 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Products and services revenue** | 145157 | 152990 | $282980 | $293995 |
| **License and royalty revenue** | 27751 | 114 | $44811 | $115 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total revenue** | $172908 | $153104 | $327791 | $294110 |

---

The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Americas** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;United States<sup>\*</sup> | $103491 | $89672 | $190309 | $165309 |
| &nbsp;&nbsp;&nbsp;&nbsp;Americas (excluding United States) | 2667 | 3419 | $6419 | 7412 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Americas** | 106158 | 93091 | 196728 | 172721 |
| **Europe, Middle East and Africa** | 34734 | 37362 | 66629 | 72083 |
| **Asia-Pacific** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;China | 23170 | 13738 | 40053 | 27662 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia-Pacific (excluding China) | 8846 | 8913 | 24381 | 21644 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Asia-Pacific** | 32016 | 22651 | 64434 | 49306 |
| Total revenue | $172908 | $153104 | $327791 | $294110 |

---

\* Includes license and royalty revenue.

(2)Includes stock-based compensation expense as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| **(in thousands)** | **2025** | **2024** | **2025** | **2024** |
| Cost of revenue | $1989 | $2247 | $4470 | $4280 |
| Research and development | 12613 | 17862 | 26719 | 34750 |
| Selling, general and administrative | 12643 | 18383 | 27132 | 35591 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stock-based compensation expense | $27245 | $38492 | $58321 | $74621 |

---

------

![a10x_logoxhorizontalxfullc.jpg](a10x_logoxhorizontalxfullc.jpg)

**10x Genomics, Inc.**

**Condensed Consolidated Balance Sheets**

*(Unaudited)*

*(In thousands)*

---

| | | |
|:---|:---|:---|
| | **June 30,<br>2025** | **December 31,<br>2024** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $397712 | $344067 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 49549 | 49335 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 49977 | 87862 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other receivables | 69090 | 606 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 68968 | 83107 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 20365 | 19410 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 655661 | 584387 |
| Property and equipment, net | 239710 | 252648 |
| Operating lease right-of-use assets | 62700 | 57290 |
| Goodwill | 4511 | 4511 |
| Intangible assets, net | 14714 | 15671 |
| Other noncurrent assets | 2674 | 4129 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $979970 | $918636 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $15938 | $12909 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation and related benefits | 26102 | 33615 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 39063 | 41165 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 21449 | 20658 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | 9669 | 9286 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 112221 | 117633 |
| Operating lease liabilities, noncurrent | 77075 | 73327 |
| Deferred revenue, noncurrent | 11270 | 12513 |
| Other noncurrent liabilities | 6125 | 5029 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 206691 | 208502 |
| Commitments and contingencies |  |  |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock | 2 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 2239924 | 2177672 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (1466867) | (1467047) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) | 220 | (493) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 773279 | 710134 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $979970 | $918636 |

---